Company Overview and News

 
Empired gets ready to raise

2017-03-21 proactiveinvestors.com.au
Empired (ASX:EPD) has been granted a trading halt by the ASX, pending details of a capital raising.

 
 
H1 FY16 Results Presentation

2016-02-26 asx.com.au

 
Cleansing Notice

2016-02-17 asx.com.au

 
Response to ASX Aware Letter

2016-01-27 asx.com.au

 
Trading Update

2016-01-22 asx.com.au

 
Response to ASX Query

2016-01-22 asx.com.au

 
Trading Halt

2016-01-21 asx.com.au

 
2015 Year-End Retirement Income Portfolio Review

2016-01-05 seekingalpha
Summary and highlights of 2015 holdings and actions.Significant decisions in 2015.Portfolio review: Down .44% for 2015.Five questions and four goals for 2016.

 
InsiderInsights.com Daily Round Up 1/4/16: Actuant, Intersections, Layne Christensen, Enterprise Products Partners

2016-01-05 seekingalpha
Tables of the top insider purchases and sales filed with the SEC on 1/4/16, based on dollar value.Dollar values often do not equate with significance when it co

 
Enterprise, Tallgrass Raise Investor Payouts

2016-01-05 247wallst
At a time when most master limited partnerships (MLPs) are holding distributions to investors flat (at best) or reducing the payouts to conserve cash, two have announced that they will raise distributions in 2016. Enterprise Product Partners L.P. (NYSE: EPD), the largest of the MLPs by market cap, and Tallgrass Energy Partners L.P. (NYSE: TEP), one of the smallest, have both announced that 2016 payouts will rise.

 
U.S. Light Crude Sails Overseas After 40 Years

2016-01-04 zacks
Following the lifting of the four-decade long U.S. oil export ban last month, the first crude tanker departed from Texas for export.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...